Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MIN-117 phase 2 study in adults with major depressive disorder
2015-000306-18Phase 2Completed
- Sponsor
- Minerva Neurosciences, Inc.
- Start
- Feb 2015
- Modality
- Classical Binding Small Molecules → Small Molecules, Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of min-117 in major depressive disorder (MDD) (4 arms), sponsored by Minerva Neurosciences, Inc. Primary endpoint: Change from baseline to Week 6 in MADRS total score. Started Feb 2015; status: completed.
02
Drugs
min-117
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on 2015-000306-18.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-000306-18.